Boehringer Ingelheim Animal Health

Greater Good Charities and Boehringer Ingelheim Kick Off Fourth Year of Good Flights Program and Celebrate Successful Transport of More Than 12,800 Shelter Pets to Adoptive Homes Including Nearly 1,300 Asymptomatic Heartworm-Positive Dogs

Retrieved on: 
Montag, April 8, 2024
DSM-IV codes, PLUS, Transport, Disease, Moxidectin, Seizure, Boehringer Ingelheim, Tablet, Diarrhea, Life, House, Dog, Lethargy, Euthanasia, Greater good, Coccidioides immitis, Safety, Terrebonne Parish, Louisiana, Good, Hookworm, Pet, Cat, Atmosphere of Earth, Itch, Animal rescue, Vomiting, Flea, Heart, Boehringer Ingelheim Animal Health, Pharmaceutical industry

To kick off the fourth year of Good Flights, a special transport of more than 45 shelter pets will take place on April 8 from Louisiana to the East Coast.

Key Points: 
  • To kick off the fourth year of Good Flights, a special transport of more than 45 shelter pets will take place on April 8 from Louisiana to the East Coast.
  • Air and ground transports for Good Flights occur approximately five times a month and many have Save a Heart pets on them.
  • “The Good Flights Program and Save a Heart initiative represents a remarkable collaboration between Greater Good Charities and Boehringer Ingelheim,” said Dr. Julie Ryan-Johnson, Senior Associate Director - Shelter Engagement Program, Boehringer Ingelheim.
  • Good Flights covers transport costs, provides mentorship, pharmaceuticals, and furnishes much needed supplies including pet crates, bowls, and leashes.

Boehringer Ingelheim Named Official Animal Health Company Partner of the Atlanta Braves

Retrieved on: 
Donnerstag, April 4, 2024
Health, Atlanta Braves, Partnership, Boehringer Ingelheim, Atlanta, Truist Park, Love, Pet, Animal, Corporation, Boehringer Ingelheim Animal Health, Fine chemical

DULUTH, Ga., April 4, 2024 /PRNewswire/ -- Boehringer Ingelheim, the largest animal health company in Georgia, is proud to announce its new partnership with the Atlanta Braves and the Atlanta Braves Foundation as the Official Animal Health Company partner, starting with the 2024 MLB season.

Key Points: 
  • DULUTH, Ga., April 4, 2024 /PRNewswire/ -- Boehringer Ingelheim, the largest animal health company in Georgia, is proud to announce its new partnership with the Atlanta Braves and the Atlanta Braves Foundation as the Official Animal Health Company partner, starting with the 2024 MLB season.
  • Randolph Legg, President of Boehringer Ingelheim Animal Health USA, expressed his excitement about the partnership, "We are thrilled to join forces with the Atlanta Braves, a team that shares our commitment to community and excellence.
  • Boehringer Ingelheim Animal Health has a significant presence in the United States, providing a wide range of products and services to improve the health and wellbeing of animals.
  • Throughout the season, fans can expect multiple activations at the ballpark and in The Battery Atlanta, further strengthening the bond between the Atlanta Braves, Boehringer Ingelheim, and the community.

New collaboration between Boehringer Ingelheim and Sleip leverages AI-technology to help detect lameness in horses

Retrieved on: 
Montag, Februar 19, 2024
Veterinarian, Doctor of Philosophy, Livestock, Artificial intelligence, Boehringer, Intelligence, DVM, Health, Animal, Farmer, Limp, Eye, Horse, Boehringer Ingelheim, Smartphone, Diagnosis, Movement, Human, Boehringer Ingelheim Animal Health, Gait, Partnership, Veterinary medicine

A new global commercial partnership between Boehringer Ingelheim and Sleip will expand access to AI to enhance detection, diagnosis and treatment of lameness in horses.

Key Points: 
  • A new global commercial partnership between Boehringer Ingelheim and Sleip will expand access to AI to enhance detection, diagnosis and treatment of lameness in horses.
  • This partnership delivers on the shared commitment of Boehringer and Sleip to deliver innovative solutions that help veterinary professionals continue to advance their profession and improve the care and wellbeing of horses.
  • Changes in gait and signs of lameness can be less pronounced at first and difficult to detect.
  • Through this collaboration, Boehringer will support the introduction of the pioneering Sleip app to the veterinary community, making this technology even more accessible.

ECO Animal Health Appoints Dr. Joachim Hasenmaier as Non-Executive Director

Retrieved on: 
Montag, Februar 12, 2024
Acquisition, The Elements of Style, Doctor of Philosophy, Boehringer Ingelheim Animal Health, Health, Growth, ECO, Veterinary medicine, MBA, AIM, Vaccine, Boehringer Ingelheim, McKinsey & Company, Animal Health, Mars, Incorporated, Ageing, Management

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces the appointment of Dr. Joachim Hasenmaier as a Non-Executive Director, with immediate effect.

Key Points: 
  • ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces the appointment of Dr. Joachim Hasenmaier as a Non-Executive Director, with immediate effect.
  • Dr. Hasenmaier is a highly experienced commercial leader with more than two decades in the international animal health industry.
  • From 2001 to 2019 he held a variety of senior roles within the animal health division at Boehringer Ingelheim, concluding as member of the Board of Managing Directors responsible for the entire animal health division.
  • Dr. Andrew Jones, Chairman of ECO, commented: “On behalf of the Board, I am delighted to welcome Joachim as a Non-Executive Director to ECO.

Specialty Sales Names Matthew Nelson as CEO

Retrieved on: 
Montag, November 6, 2023
Veterinary, Agriculture, Natural Resources, Finance, Health, Chemicals, Plastics, Professional Services, Manufacturing, Boehringer Ingelheim, Sales, Pig, Food, Zoetis, Poultry, Farmer, Animal, National Dairy Development Board, Culture, Marketing, Boehringer Ingelheim Animal Health, Dairy

“Hoofstrong”), the leading provider of hoof health solutions to the U.S. dairy industry, today announced the appointment of Matthew Nelson as CEO.

Key Points: 
  • “Hoofstrong”), the leading provider of hoof health solutions to the U.S. dairy industry, today announced the appointment of Matthew Nelson as CEO.
  • Specialty Sales is a portfolio company of Kainos Capital, a consumer-focused private equity firm that invests in strategically relevant growth companies in the food, pet, animal health, specialty distribution and services industries.
  • Mr. Alsup said, “We are pleased to welcome Matt to Specialty Sales.
  • Matt is uniquely qualified to lead Specialty Sales given his professional background that spans animal health and nutrition across bovine, poultry, swine, equine and companion animals.

Boehringer Ingelheim, WoofTrax Kick Off Dog Walking Challenge to Help Shelter Dogs In Need

Retrieved on: 
Mittwoch, November 1, 2023
Challenge, Boehringer Ingelheim Animal Health, Veterinarian, App Store (iOS/iPadOS), Health, Therapy, Human, Parasitism, Livestock, Google Play, Pet, Boehringer Ingelheim, Farmer, Walking, STEP, Love, Animal, Shelter, Dog, Associate, Mobile phone, Pharmaceutical industry, Fine chemical

DULUTH, Ga., Nov. 1, 2023 /PRNewswire/ -- Boehringer Ingelheim, a leader in animal health innovation, has teamed up for the fourth year with WoofTrax, a fundraising app that supports animal shelters and rescues, to launch the 2023 STEP UP FOR SHELTERS® Challenge. This initiative allows participants to contribute to animal shelters by simply walking their dogs using the WoofTrax app.

Key Points: 
  • This initiative allows participants to contribute to animal shelters by simply walking their dogs using the WoofTrax app.
  • "Through the 2023 STEP UP FOR SHELTERS® Challenge we can work together to protect shelter dogs in need.
  • Additionally, each walk will earn 5 cents for the participant's selected WoofTrax animal charity, with a maximum total challenge donation of $10,000.
  • WoofTrax, in collaboration with Boehringer Ingelheim, will allocate funds to the users' selected animal shelters based on the number of walks taken during the challenge.

Global Veterinary Vaccines Market 2023-2029: Merck & Co. Dominates the Competition, Closely Followed by Boehringer Ingelheim, Ceva Sante Animale, and Zoetis

Retrieved on: 
Mittwoch, August 23, 2023
Benchmark, Vaccine, Antigen, Partnership, Vaccination, Marketing, Veterinarian, Aquaculture, Livestock, Infection, Uniloc USA, Inc. v. Microsoft Corp., Iowa State University, Infant, Compound annual growth rate, Schering-Plough, Air Liquide, Ceva, Acquisition, Animal, Artemis Technologies, Dog, Cattle, Rabbit, Growth, Merck, Merck & Co., Enrofloxacin, Health, Pig, Virbac, Disease, Boehringer Ingelheim Animal Health, Bordetella bronchiseptica, Cat, Fine chemical, Pharmaceutical industry, Pet

To maintain a competitive edge and meet changing demands, market participants are employing various strategies, such as acquisitions and partnerships.

Key Points: 
  • To maintain a competitive edge and meet changing demands, market participants are employing various strategies, such as acquisitions and partnerships.
  • In terms of market competition, Merck & Co., Inc. emerged as a forerunner in the market, closely followed by companies like Boehringer Ingelheim International GmbH, Ceva Sante Animale, and Zoetis Inc.
  • Apr-2022: Ceva Sante Animale signed an agreement with Mitsui & Co., Ltd., a Japan-based investment, and trading company to form Ceva Bussan Animal Health K.K.
  • This Joint venture aims to boost the broadening of the veterinary laboratory to Japan, a critical market for the business.

Boehringer Ingelheim Receives FDA Approval for NexGard® PLUS (afoxolaner, moxidectin and pyrantel chewable tablets): A Beef-Flavored Soft Chew That Protects Dogs from Internal and External Parasites

Retrieved on: 
Donnerstag, Juli 20, 2023
Seizure, Afoxolaner, Human, Companion Animal Parasite Council, Tremor, Parasitism, Prevalence, Diarrhea, Breeding, Veterinarian, Dog, Farmer, Coccidioides immitis, Season, Health, Ataxia, DSM-IV codes, Livestock, Animal Health, Moxidectin, Tick, Tablet, Boehringer Ingelheim, Vomiting, CAPC, Animal, Patient, Freezing, Lethargy, Eprinomectin, Pet, Itch, FDA, Ivermectin, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Praziquantel, Internal, DVM, Veterinary medicine, Food, Boehringer Ingelheim Animal Health, Cat, Bottled water, Medical device, Vaccine, Pharmaceutical industry, Dietary supplement

By combining internal and external parasite protection in a tasty, beef-flavored soft chew, NexGard® PLUS helps make monthly compliance easy and enjoyable for pets and pet owners.

Key Points: 
  • By combining internal and external parasite protection in a tasty, beef-flavored soft chew, NexGard® PLUS helps make monthly compliance easy and enjoyable for pets and pet owners.
  • Each NexGard® PLUS chew has the same proven afoxolaner dose prescribed to millions of dogs in NexGard® (afoxolaner),6 and an optimized dose of moxidectin that is proven safe and effective.
  • To further enable compliance, veterinarians can prescribe 3-dose and 6-dose presentations to best support the needs of their canine patients.
  • NexGard® PLUS (afoxolaner, moxidectin, and pyrantel chewable tablets) are for use in dogs only.

Invetx Appoints Dr. Marcus Remmers, Novo Holdings Partner and Animal Health Industry Leader, to Board of Directors

Retrieved on: 
Montag, Juni 26, 2023
Biotechnology, Pharmaceutical, Health, Veterinary, Boehringer Ingelheim Animal Health, Leibniz Institute for Polymer Research, Merck & Co., DSM, University, Therapy, Veterinary medicine, Global health, Multimedia, Animal Health, Doctor of Philosophy, Max Planck Institute for Polymer Research, Chemistry, Novo Holdings A/S, Dog, Max Planck Society, University of Freiburg

Invetx, a pioneer in protein-based therapeutics for animal health, today announced the appointment of Dr. Marcus Remmers to its board of directors.

Key Points: 
  • Invetx, a pioneer in protein-based therapeutics for animal health, today announced the appointment of Dr. Marcus Remmers to its board of directors.
  • View the full release here: https://www.businesswire.com/news/home/20230626564216/en/
    Dr. Marcus Remmers joins the board of directors at Invetx.
  • (Photo: Business Wire)
    “We are pleased to welcome Dr. Remmers, an accomplished life sciences executive with significant veterinary biologics and animal health expertise, to our board of directors,” said Juergen Horn, PhD, chief executive officer, Invetx.
  • “I am excited to join the board of directors of Invetx and be part of the company’s remarkable journey,” said Dr. Remmers.

Xoran Technologies® Announces New Independent Director

Retrieved on: 
Dienstag, Mai 2, 2023
Boehringer Ingelheim Animal Health, CT, Executive, CUNY, BS, ANN, Veterinarian, Veterinary medicine, Medicine, Google Images, Corporate services, City University of New York, Biology, Health, Union College, City University, Management, Medical imaging

ANN ARBOR, Mich., May 2, 2023 /PRNewswire/ -- Xoran Technologies®, a leader in providing innovative CT imaging solutions, announces Donald Schwartz has joined Xoran's Board of Managers as an Independent Director. Schwartz's animal health industry experience and broad expertise in executing business strategies will advance Xoran's organizational goal to increase accessibility to CT imaging technology across veterinary medicine. 

Key Points: 
  • ANN ARBOR, Mich., May 2, 2023 /PRNewswire/ -- Xoran Technologies®, a leader in providing innovative CT imaging solutions, announces Donald Schwartz has joined Xoran's Board of Managers as an Independent Director.
  • "We are gratified to welcome Donald Schwartz to our Board as an Independent Director," says Jacqueline Vestevich, Xoran's Executive Chairman.
  • "Don's vast experience and expertise in animal health will help Xoran accelerate value creation and promote meaningful growth in our burgeoning veterinary business."
  • Xoran is committed to equipping veterinarians with diagnostic imaging technology that increases efficiency and improves treatment outcomes in veterinary medicine.